Literature DB >> 34474722

Serum Ferritin and the Risk of Metabolic Syndrome: A Systematic Review and Dose-Response Meta-Analysis of Cross-sectional Studies.

Wei Chun Bai Zhang1, Yang Xing2, Bing Shao3.   

Abstract

OBJECTIVE: This study aims to assess the dose-response relationship between serum ferritin (SF) and metabolic syndrome (MetS) in the two sexes.
METHODS: We searched for articles on PubMed, the Cochrane Library, EMBASE, and the Web of Science databases that were published from 1950 to 2020. The summary odds ratio ( OR) and 95% confidence interval ( CI) of the association between SF and MetS were estimated using a random-effects model through a meta-analysis. Based on the methods described by Greenland and Longnecker, we explored the dose-response relationship between the two sexes.
RESULTS: This study included 14 studies and 74,710 samples. The results of the classical meta-analysis showed that SF was positively associated with MetS ( OR = 1.77, 95% CI: 1.59-1.98). Regarding the components of MetS (8 studies included), the results showed that SF was positively associated with abdominal obesity ( OR = 1.42, 95% CI: 1.24-1.62), elevated fasting plasma glucose ( OR = 1.84, 95% CI: 1.50-2.25), elevated blood pressure ( OR = 1.17, 95% CI: 1.08-1.26), elevated triglycerides ( OR= 2.09, 95% CI: 1.72-2.54), and reduced high-density lipoprotein cholesterol ( OR = 1.33, 95% CI: 1.19-1.49). In the linear dose-response meta-analysis, the ORs of males, females, and postmenopausal females were 1.14 (95% CI: 1.13-1.16), 1.32 (95% CI: 1.26-1.39), and 1.34 (95% CI: 1.22-1.47), respectively.
CONCLUSIONS: Our study shows that SF is significantly and positively associated with MetS, and the risk in the male population is higher than that in the female population. This finding also supports the recommendation of using SF as an early warning marker of MetS.
Copyright © 2021 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Entities:  

Keywords:  Dose-response relationship; Meta-analysis; Metabolic syndrome; Serum ferritin

Mesh:

Substances:

Year:  2021        PMID: 34474722     DOI: 10.3967/bes2021.086

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  4 in total

1.  Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients.

Authors:  Qingling Wang; Mingyu Zhu; Hu Li; Peizhan Chen; Mingjie Wang; Leilei Gu; Xinxin Zhang; Li Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-17       Impact factor: 3.249

2.  Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern population-based cross-sectional study.

Authors:  Neyla S Al Akl; Olfa Khalifa; Khaoula Errafii; Abdelilah Arredouani
Journal:  Sci Rep       Date:  2021-12-16       Impact factor: 4.379

Review 3.  The Prognostic Performance of Ferritin in Patients with Acute Myocardial Infarction: A Systematic Review.

Authors:  Crischentian Brinza; Mariana Floria; Iolanda Valentina Popa; Alexandru Burlacu
Journal:  Diagnostics (Basel)       Date:  2022-02-13

4.  Sex-Specific Associations between Serum Ferritin and Osteosarcopenic Obesity in Adults Aged over 50 Years.

Authors:  Sung-Joon Chung; Han Sol Lim; Mi-Yeon Lee; Yong-Taek Lee; Kyung Jae Yoon; Chul-Hyun Park
Journal:  Nutrients       Date:  2022-09-28       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.